ILLUMINA INC.

Company Snapshot

Founded: 1998
Entity Type: Public
Employees: 8,970
Region: Americas
Revenue: $4,343.0 Millions
Revenue Year: 2025
Segment: Core Illumina
Headquarter: California, U.S.
Key Geographics: Americas, Europe, Middle East, Africa, China, Asia-Pacific
Corporate Address: 5200 Illumina Way, San Diego, California, 92122 U.S. Tel. +1- 858-202-4500 www.illumina.com

Company Overview

Illumina Inc. develops, manufactures, and markets DNA sequencing systems, microarray platforms, reagents, and analysis software for studying genetic variation and function. It offers comprehensive sequencing and array solutions for academic, clinical, and translational uses in more than 150 countries. In cancer profiling, it is positioned within the next-generation sequencing segment, with activities spanning research-use and clinical testing workflows. Its technology framework supports comprehensive genomic profiling of solid tumors through DNA- and RNA-based assays, integrated informatics, and bioinformatics pipelines designed for large-scale molecular analysis.

Illumina maintains manufacturing, R&D, and commercial facilities across North America, Europe, and Asia-Pacific through direct sales and distributor networks.

Financial Highlights (FY 2025)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

ILLUMINA INC. In Reports

Cancer Profiling and Pathways: Technologies and Global Markets

According to BCC Research detailed report on Cancer Profiling and Pathways Technologies Market using 2024 as the base year, 2025 as the estimate year and CAGR projections for the period 2025-2030.

Global DNA Read, Write, and Edit Market

BCC Research detailed report on DNA Read, Write and Edit Market includes global revenue ($ Million) for the base year 2024 and estimated data for the forecast period 2025 through 2030.

Noninvasive Cancer Diagnostics: Technologies and Global Markets

According to BCC Research detailed report on noninvasive cancer diagnostic market global revenue ($ Million) for the base year 2024, estimated data for 2025, and forecasts through 2026-2030.

Company's Business Segments

  • Core Illumina : It includes consumables, instruments, services and other revenue.

Applications/End User Industries

  • Next-Generation Sequencing (NGS)
  • Cutting-Edge Array Scanners
  • In Vitro Diagnostic (IVD)
  • Reagents
  • Microarray Kits
  • Genotyping
  • Epigenetic Analysis
  • Vitro Diagnostic
  • Oncology Comprehensive
  • Sequencing Platform Comparison
  • Designstudio Software
  • Trusight Oncology
  • Basespace Sequence Hub
  • Dragen Secondary Analysis
  • Illumina Connected Analytics
  • Genomic Insights
  • Oncology Clinical Research
  • Laboratory Information Management System
  • Correlation Engine
  • Microarray Data Analysis
  • DNA Prep Portfolio
  • Life Sciences
AI Sentiment